Fig. 1: Patient profiles of percent change in serum κ free light chain (κFLC) concentrations from baseline after MDX-1097 intravenous infusion, presented by dose cohort. | Blood Cancer Journal

Fig. 1: Patient profiles of percent change in serum κ free light chain (κFLC) concentrations from baseline after MDX-1097 intravenous infusion, presented by dose cohort.

From: A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma

Fig. 1

Cohort 1 (0.3 mg/kg; a, e), Cohort 2 (1.0 mg/kg; b, f), Cohort 3 (3.0 mg/kg; c, g), and Cohort 4 (10 mg/kg; d, h). Baseline serum concentrations were assessed at −30 min pre-infusion (0) and then post infusion at specified intervals up to day 45 (a–d) and during the follow-up phase for a total of 135 days (e–h). There was no apparent change in serum λFLC concentration throughout the study and the changes in serum FLC ratios (κ:λ) were consistent with the fluctuations in serum κFLC concentrations. κFLC, kappa free light chain; λFLC, lambda free light chain

Back to article page